| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02421354 Details | 2019-05-15 Interventional | 2 | 8 | Nivolumab Hepatomegaly Polycythemia Polycythemia Ve… Primary Myelofi… Splenomegaly Thrombocythemia… Thrombocytosis Myelofibrosis T… Polycythemia Ve… | - - | |||
| NCT02987920 Details | 2019-05-14 Interventional | 4 | 23 | Acetaminophen Celecoxib Dextromethorpha… Gabapentin Hydromorphone Ketorolac Levomethorphan Oxycodone Pantoprazole Pain, Postopera… | The surgeon changed pain control protocol for all patients. Continued enrollment impossible
under approved protocol. - | |||
| NCT02929498 2016-002294-35 Details | 2019-05-14 Interventional | 1/2 | 7 | Azacitidine Myelodysplastic… Preleukemia Syndrome Myelodysplastic… | The risk benefit in the study population does not favor continuation of the study - | |||
| NCT02410382 Details | 2019-05-14 Interventional | 2 | 79 | Dexamethasone Carcinoma, Non-… Lung Neoplasms Head and Neck C… Non-small Cell … | IRB suspension, did not resume - | |||
| NCT02258529 Details | 2019-05-14 Interventional | 2 | 10 | Idelalisib Rituximab Leukemia, Lymph… Lymphoma Lymphoma, Folli… Follicular Lymp… Small Lymphocyt… | - Due to the early termination of the study, efficacy data were not available for all participants, and therefore the prespecified analyses were not conducted. | |||
| NCT01756560 Details | 2019-05-14 Interventional | 4 | 2 | Bupivacaine Duration of Pai… | Unable to continue research due to time constraints - | |||
| NCT01328002 Details | 2019-05-14 Interventional | 2 | 116 | Levomilnacipran Milnacipran Fibromyalgia Myofascial Pain… Primary Fibromy… | - Due to the early termination of the study, no firm conclusions about the use of milnacipran in pediatric patients for the treatment of primary fibromyalgia can be drawn. | |||
| NCT03457753 Details | 2019-05-13 Interventional | 2 | 0 | Riluzole Amyotrophic Lat… Motor Neuron Di… Sclerosis ALS | The Sponsor stopped the study due to a change in study plans - | |||
| NCT03752190 Details | 2019-05-10 Interventional | 4 | 0 | Cosyntropin Adrenal Insuffi… | Change in personnel leading to inability to conduct study. - | |||
| NCT03645876 Details | 2019-05-10 Interventional | 2 | 12 | Capecitabine Oxaliplatin Colorectal Neop… Metastatic Colo… | The study was terminated early due to company decision - | |||
| NCT03490916 Details | 2019-05-10 Interventional | 4 | 18 | Acetazolamide Altitude Sickne… Edema Hypertension, P… Pulmonary Edema High Altitude P… | PI was unable to continue to gather data during the trip during to medical illness Due to Investigator illness, although participants were enrolled, no participants were randomized to receive interventions and did not receive study drug. | |||
| NCT01875653 2015-001984-38 Details | 2019-05-10 Interventional | 3 | 4 | Molgramostim Sargramostim Melanoma Stage III Melan… Stage IV Melano… | - - | |||
| NCT00814593 Details | 2019-05-10 Interventional | 2 | 0 | Carmustine Central Nervous… Glioblastoma Nervous System … Brain and Centr… | Hoag Hospital ceased support. - | |||
| NCT00704821 Details | 2019-05-10 Interventional | 1 | 76 | Docetaxel Neoplasms Advanced Cancer | - - | |||
| NCT02186301 Details | 2019-05-07 Interventional | 2/3 | 100 | Erlotinib Hydro… Carcinoma, Non-… Non-Small Cell … | Sponsor discontinued development of CO-1686 for NSCLC - | |||
| NCT01536717 2011-004307-20 Details | 2019-05-07 Interventional | 4 | 36 | Carticaine Aortic Valve Di… Heart Septal De… Heart Septal De… Aortic Valve Di… Atrial Septal D… Diseases of Mit… Intracardiac My… | - - | |||
| NCT03775707 Details | 2019-05-06 Interventional | 2 | 0 | Antibodies Lenvatinib Carcinoma Carcinoma, Hepa… Hepatocellular … | Protocol modification - | |||
| NCT03752138 Details | 2019-05-06 Interventional | 1 | 0 | Decitabine Leukemia Leukemia, Myelo… Leukemia, Myelo… Recurrent Acute… Refractory Acut… | The supporting pharamceutical company elected not to pursue this study at this time. - | |||
| NCT02895529 Details | 2019-05-06 Interventional | 4 | 61 | Caspofungin Itraconazole Hematologic Neo… | Study is a commitment for license renew, we target on Apr19 submission, considering timeline, a
cut off should be scheduled in Apr18. - | |||
| NCT01403389 Details | 2019-05-06 Interventional | 2 | 8 | Eculizumab Delayed Graft F… Delayed Functio… | After interim analysis, the pilot study was terminated and modified to a larger multicenter
study (NCT01919346) to better assess efficacy. - |